Antibe Therapeutics Announces Appointment Of The Giordano Group, Inc, A Division Of Network 1 Financial Securities LLC, As US-BASED Investor Relations Consultant

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc (“Antibe” or the “Company”) (TSXV:ATE, OTCQX:ATBPF) has retained the Giordano Group, Inc (“Giordano Group”), a division of Network 1 Financial Securities LLC (“Network 1”), to provide investor relations consulting services for the United States.

The Giordano Group has many years of experience in designing and executing Investor Relations programs for emerging life science companies in the United States, including non-deal and deal-related road shows throughout the country. Network 1 is a full service FINRA registered broker dealer; it was established in 1983, and is headquartered in Red Bank, New Jersey.

The agreement with the Giordano Group is subject to the approval of Canadian securities regulators. It is for a duration of 6 months and provides for an investor relations consulting fee of USD $5,000 per month.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.

Antibe’s subsidiary, Citagenix Inc. (Citagenix), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) and no stock exchange, securities commission or other regulatory authority accepts responsibility for the adequacy or accuracy of this release nor approved or disapproved of the information contained herein.

Forward-Looking Information

This news release includes certain forward-looking statements which may include, but are not limited to, royalty payments and milestone payments from Knight. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, not achieving commercial revenue from Antibe’s anti-inflammatory and pain drugs, not achieving the milestone specified in the license agreement, risks associated with drug development generally, not obtaining future financing on adequate terms, or at all, anticipated sales not achieving expected volumes and not obtaining TSX Venture Exchange final approval for the transactions described herein. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.